THE SHARE: Change: 0.00 SEK (-3.57%) / Price: 0.11 SEK / Apr 16, 2026, 6:00 pm (CEST)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

News

  • 13 Nov, 2019
    Spago Nanomedical delårsrapport juli – september 2019
  • 16 Oct, 2019
    Kallelse till extra bolagsstämma i Spago Nanomedical AB (publ)
  • 28 Sep, 2019
    First patient dosed in the SPAGOPIX-01 study
  • 28 Sep, 2019
    Första patienten doserad i SPAGOPIX-01 studien
  • 26 Aug, 2019
    Spago Nanomedical has initiated the clinical trial SPAGOPIX-01
  • 26 Aug, 2019
    Spago Nanomedical har initierat den kliniska studien SPAGOPIX-01
  • 22 Aug, 2019
    Spago Nanomedical delårsrapport april – juni 2019
  • 5 Aug, 2019
    SpagoPix produktpatent i godkänns i Europa
  • 8 May, 2019
    Eugen Steiner ny ordförande
  • 25 Apr, 2019
    Spago Nanomedical delårsrapport januari – mars 2019
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 38
  • Previous
  • Next
Back

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2026 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications